Bone Biologics Corp

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Operations

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Revenues · $ · - · $ · - · $ · - · $ · -
Operating expenses
Research and development	429,747	1,574,850	1,025,814	6,460,747
General and administrative	521,274	506,040	1,638,409	1,807,548
Total operating expenses	951,021	2,080,890	2,664,223	8,268,295
Loss from operations	(951,021)	(2,080,890)	(2,664,223)	(8,268,295)
Other income (expenses)
Change in fair value of warrant liability	(9,974)	160,645	38,122	867,930
Interest income	19,993	536	35,396	1,519
Total other income (expenses)	10,019	161,181	73,518	869,449
Net loss	(941,002)	(1,919,709)	(2,590,705)	(7,398,846)
Deemed dividend on warrant inducements	(3,212,504)	-	(3,212,504)	-
Net loss attributable to common stockholders	$(4,153,506)	$(1,919,709)	$(5,803,209)	$(7,398,846)
Weighted average shares of common outstanding – basic and diluted	1,753,409	391,854	1,196,295	197,855
Loss per share – attributable to common stockholders, basic and diluted	$(2.37)	$(4.90)	$(4.85)	$(37.40)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.